Targeting PD-1/PD-L1 by antibodies is minimally effective in several cancers, including renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC) [90, 91]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.